Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Operating Leases (2019 - 2025)

International Stem Cell (ISCO) has disclosed Operating Leases for 7 consecutive years, with $103000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Operating Leases fell 49.26% to $103000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $103000.0, a 49.26% decrease, with the full-year FY2024 number at $115000.0, down 74.16% from a year prior.
  • Operating Leases was $103000.0 for Q3 2025 at International Stem Cell, down from $204000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $950000.0 in Q4 2021 to a low of $103000.0 in Q3 2025.
  • A 5-year average of $532315.8 and a median of $588000.0 in 2023 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: grew 21.09% in 2022, then crashed 74.16% in 2024.
  • International Stem Cell's Operating Leases stood at $950000.0 in 2021, then fell by 24.21% to $720000.0 in 2022, then plummeted by 38.19% to $445000.0 in 2023, then plummeted by 74.16% to $115000.0 in 2024, then fell by 10.43% to $103000.0 in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Operating Leases are $103000.0 (Q3 2025), $204000.0 (Q2 2025), and $302000.0 (Q1 2025).